医薬経済は医療・医薬を取り巻く環境の“いま”にフォーカス！

MENU

RISFAX　June 29, 2017

日本語

Drug Vial Optimization (DVO)” is “essential”
LDP’s administrative reform headquarters vice chairman Suzuki, gathering of patients is also expected in future

MHLW to consider “more reward” if manufacturing cost is clear
Under the cost calculation method, both sides opposed to “reward is insufficient” at present

Cost-effectiveness assessment: Price to be adjusted “after” NHI price listing based on outcome in case of new drugs
Japan Medical Association (JMA) worried about inflow of cheap hepatitis C drugs from Indian generic makers
Takeda Pharmaceutical’s meeting of shareholders rejects a shareholder’s proposal to abolish advisor system
The University of Tokyo professor Kiyono also hoping for use of “MucoRice” for DDS (Drug Delivery System)
Wakayama Prefecture gives Yamamoto Kagaku Kougyou business suspension order on mixing unauthorized Chinese API
Tokyo metropolitan government Director Kono: Interim report of panel on counterfeit HARVONI, “effective to a certain degree”
Takeda Pharmaceutical decides directors. CFO Kehoe newly assigned
Chuikyo (Central Social Insurance Medical Council) accepts listing of medical devices of Tokai Medical and Medtronic
MHLW gives 11 medical institutions urgent order to temporarily suspend regenerative medicine